Regimed Medical

Regimed Medical, a sole proprietorship and minority-owned, Black American-owned small disadvantaged business based in O'Fallon, Missouri, supplies pharmaceuticals and medical-surgical supplies to federal healthcare agencies as a prime contractor exclusively (100% of awards), competing predominantly under small-business set-asides on Consolidated Mail Outpatient Pharmacy procurement for the Department of Veterans Affairs and specialized oncology pharmaceuticals for the National Cancer Institute.

Regimed Medical's federal capability portfolio centers on the procurement and delivery of branded and generic pharmaceuticals—including nilotinib (Tasigna), drospirenone, hydrocortisone acetate, ferrous sulfate, venlafaxine, and atropine-pralidoxime compounds—and medical-surgical supplies such as feeding syringes, insulin pump reservoirs, catheter sets, and lancets. The company holds a $6.34 million Indefinite Delivery Contract (Total Small Business Set-Aside) with the National Cancer Institute awarded March 27, 2023, with ultimate completion in March 2027. Under this IDC, Regimed Medical has delivered four task orders: a $951 thousand delivery order (March 2023) for 150mg and 200mg nilotinib capsules; a $780 thousand delivery order (September 2023) for 150mg and 200mg nilotinib capsules; a $1.7 million delivery order (November 2023) for 150mg and 200mg nilotinib tablets; and a $219 thousand delivery order (March 2025) for 200mg nilotinib tablets. Recent representative VA awards include a $292 thousand July 2026 purchase order to Veterans Integrated Service Network 22 for drospirenone 4mg tablets (1,485 units), a $139 thousand April 2026 award from Veterans Integrated Service Network 15 for hydrocortisone acetate 25mg rectal suppositories (22,488 units of 12-count and 6,744 units of 24-count packaging for seven CMOP facilities), and a $196 thousand December 2024 purchase order to Veterans Integrated Service Network 12 for naltrexone 50mg tablets (7,488 bottles) for the Hines CMOP facility.

Customer concentration is stark and bifurcated. Veterans Affairs networks account for 77% of award count (135 awards, $4.4 million combined potential value) but only 49% of total potential dollars. Within the VA customer base, Veterans Integrated Service Network 15 dominates with 55 awards totaling $2.1 million, followed by Veterans Integrated Service Network 7 (34 awards, $440 thousand), Veterans Integrated Service Network 1 (19 awards, $349 thousand), Veterans Integrated Service Network 12 (15 awards, $1.1 million), and Veterans Integrated Service Network 22 (12 awards, $419 thousand). The National Institutes of Health National Cancer Institute, by contrast, represents only 6 awards (3% of count) but $10.2 million in combined potential value (50% of total dollars), anchored by the $6.34 million IDC. The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response holds a single $4.2 million award. Together, HHS agencies represent 89% of combined potential value across just seven awards.

Activity has declined materially over the past five years—nine awards in 2022, ten in 2023, seven in 2024, four in 2025, and four in 2026 year-to-date—though the trajectory reflects a shift toward higher-value NCI delivery orders rather than volume contraction at the VA. Combined potential value across 175 prime awards totals $20.3 million, with $9.9 million obligated (49% realization). Only one award with ultimate completion within the next twenty-four months is present in the source data—a $140 thousand item—indicating minimal recompete cliff exposure in the near term but also limited near-term pipeline visibility.

Regimed Medical competes under Total Small Business Set-Aside designations on approximately 60% of its VA awards and operates across NAICS 325412 (Pharmaceutical Preparation Manufacturing), 325413 (In-Vitro Diagnostic Substance Manufacturing), and related pharmaceutical-supply codes. The vendor has no subcontract footprint and does not participate in GWACs, BPAs, or agency-wide IDIQs; all work flows through direct purchase orders and the single NCI IDC.

DISTRIBUTE MEDICAL & LABORATORY SUPPLIES & EQUIPMENT. ALL HOSPITAL & MEDICAL NEEDS FOR DISPOSABLE & NONDISPOSABLE ITEMS. DISTRIBUTE ALL PHARMACEUTICAL SUPPLIES